TECH
TECH
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
0
$0
Total Volume
$0
6 transactions
Net Activity
+$0
Net buying
Sentiment Rating
Neutral / BalancedCEO Conviction Index
No Recent Signal
Key Drivers
- •Balanced trading volume with net neutral buying and selling activity.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
TECH has an insider buy conviction of 50%, compared to the Unknown sector buy average of 20%.
Multiple Insiders
S - Sale+OE Insiders
$0 total
Over the last 90 days, corporate insiders at TECH (TECH) engaged in a total of 6 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 0 were sales. The total volume of insider trading reached $0.
The net insider activity for TECH shows a net buying bias of $0. This activity represents a 50% buy ratio, suggesting that insiders are currently neutral on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (S - Sale+OE Insiders), who traded 2.9K shares valued at $0 on May 8, 2026.
Quick Actions
Related News & Analyst Reports
Read original insights and educational research covering TECH and the Unknown sector.
The AI Circular Valuation Bubble: Inside the Venture-Cloud Loop
An in-depth investigation into how technology giants and AI startups engage in circular capital flows, investing venture capital in exchange for cloud services and hardware, creating a closed-loop economy that artificially inflates valuations.
The Biotech Executive Playbook: Tracking Clinical Phase SEC Filings
An empirical study on how clinical-stage biotech executives execute Form 4 open-market purchases ahead of trial data releases, outlining the regulatory gaps and alpha potential of clinical insider tracking.
Evaluating a16z Web3 Spinoffs: Insider Activity in Tech Convergence Stocks
Andreessen Horowitz has backed dozens of Web3 startups that later went public. This report tracks board-member Form 4 activity at a16z-affiliated tech convergence companies to identify post-IPO insider conviction signals.
Tracking Insider Activity in Biotech: High Stakes and Hidden Signals
Biotech insiders possess unique asymmetric information, clinical results, FDA feedback, partnership negotiations. This guide explains how to track Form 4 activity at pre-commercial biotechs, what position sizes matter, and how to avoid false signals near data events.
Venture-Backed Biotech IPOs: Inside the 2026 Buying Spree
2026 saw a resurgence of venture-backed biotech IPOs, accompanied by unusually high post-lockup insider buying. This report documents the specific Form 4 cluster events, purchase sizes, and 90-day price performance across a dozen recent biotech offerings.
Why Tech Executives Voluntarily Accept Stock Over Cash Compensation
Many tech executives voluntarily elect equity compensation over cash, and these elections appear as Form 4 events. This report explains why this practice is widespread in tech, how to interpret voluntary equity elections on Form 4, and what they signal about executive sentiment.
FAQs About TECH Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for TECH.